Author:
Kang Jukyung,Kim Sang Yeop,Vallejo Daniel,Hageman Tyler S.,White Derek R.,Benet Alexander,Coghlan Jill,Sen K. Ilker,Ford Michael,Saveliev Sergei,Tolbert Thomas J.,Weis David D.,Schwendeman Steven P.,Ruotolo Brandon T.,Schwendeman Anna
Subject
Pharmaceutical Science,General Medicine,Biotechnology
Reference88 articles.
1. CDER/CBER, FDA, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry, (last accessed: 3 March 2019).
2. European Medicines Agency, European public assessment reports on centrally authorised biosimilar medicines, (last accessed: 5 September 2019).
3. U.S. Food and Drug Administration, Biosimilar product information, (last accessed: 5 November 2019).
4. Therapeutic monoclonal antibodies: strategies and challenges for biosimilars development;Calvo;Curr. Med. Chem.,2012
5. Clinical considerations for biosimilar antibodies;Mellstedt;Eur. J. Cancer, Suppl.,2013
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献